Global medical technology firm BD, also known as Becton, Dickinson and Co., on Thursday said it entered into the treatment of chronic venous insufficiency with the acquisition of Venclose Inc.
Venclose provides solutions for the treatment of CVI — a disease that is the result of malfunctioning valves and can lead to varicose veins. It represents a significant and growing therapeutic need within the health care system — impacting up to 40% of women and 17% of men in the U.S.
“We’re committed to setting a new standard of excellence for people living with venous disease, and that starts with providing physicians with innovative technologies,” said Paddy O’Brien, worldwide president of Peripheral Intervention for BD. “Our acquisition of Venclose will enable us to offer a more robust portfolio of solutions to physicians who are treating the full range of venous conditions.”
Venclose was founded in 2014 to enhance the treatment of CVI through radiofrequency ablation technology. The company has since been committed to delivering technological advancements and procedural efficiencies to physicians treating CVI, while also helping to improve patient satisfaction. The Venclose System is currently available in a variety of health care settings across the U.S. and areas of Europe.
Terms of the transaction were not disclosed. The transaction is expected to be immaterial to BD’s fiscal 2022 financial results.